Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.
2.

Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.

Skouby SO, Gram J, Andersen LF, Sidelmann J, Petersen KR, Jespersen J.

Am J Obstet Gynecol. 2002 May;186(5):969-77.

PMID:
12015523
3.

Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.

Taskinen MR, Puolakka J, Pyörälä T, Luotola H, Bjäörn M, Kääriänen J, Lahdenperä S, Ehnholm C.

Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1215-21.

4.

Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.

Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC.

Arch Intern Med. 2000 Nov 27;160(21):3315-25.

PMID:
11088095
5.

Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.

Peverill RE, Teede HJ, Smolich JJ, Malan E, Kotsopoulos D, Tipping PG, McGrath BP.

Clin Sci (Lond). 2001 Jul;101(1):93-9.

PMID:
11410120
6.

Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.

Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.

Climacteric. 2002 Dec;5(4):341-50.

PMID:
12626213
8.

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.

Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3071-8.

9.
10.

Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study.

Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO; Prospective Collaborative Danish Climacteric Study.

BJOG. 2003 Jun;110(6):541-7.

11.

Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy.

Nozaki M, Ogata R, Koera K, Hashimoto K, Nakano H.

Climacteric. 1999 Jun;2(2):124-30.

PMID:
11910665
12.

Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.

Raudaskoski T, Tapanainen J, Tomás E, Luotola H, Pekonen F, Ronni-Sivula H, Timonen H, Riphagen F, Laatikainen T.

BJOG. 2002 Feb;109(2):136-44.

13.

Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors.

Chen FP, Lee N, Soong YK, Huang KE.

Menopause. 2001 Sep-Oct;8(5):347-52.

PMID:
11528361
14.
15.
16.

Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women.

Yilmazer M, Fenkci V, Fenkci S, Sonmezer M, Aktepe O, Altindis M, Kurtay G.

Maturitas. 2003 Dec 10;46(4):245-53.

PMID:
14625121
17.

Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.

Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.

Gynecol Endocrinol. 2005 Mar;20(3):144-9.

PMID:
16019353
19.

Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.

Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ.

Br J Haematol. 2004 Mar;124(6):802-8.

PMID:
15009069
20.

Supplemental Content

Support Center